Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Next Previous
X
Search
Trial Profile

A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium difficile infections; Diarrhoea
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Optimer Pharmaceuticals

    • Most Recent Events

    • 08 Oct 2014 Results presented at the IDWeek 2014, according to a Cubist Pharmaceuticals media release.
    • 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 27 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrial.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top